Overview

A Pilot Study of KPL-914 in Recurrent Pericarditis

Status:
Completed
Trial end date:
2019-05-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the preliminary efficacy and safety of KPL-914 treatment in participants with recurrent pericarditis.
Phase:
Phase 2
Details
Lead Sponsor:
Kiniksa Pharmaceuticals (UK), Ltd.
Kiniksa Pharmaceuticals, Ltd.
Treatments:
Rilonacept